UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2841) 2841
Book Chapter (7) 7
Publication (3) 3
Book / eBook (2) 2
Dissertation (1) 1
Streaming Video (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
camptothecin - analogs & derivatives (2401) 2401
science & technology (2348) 2348
humans (2342) 2342
life sciences & biomedicine (2216) 2216
oncology (1402) 1402
female (1368) 1368
camptothecin - administration & dosage (1366) 1366
male (1293) 1293
camptothecin - pharmacokinetics (1192) 1192
irinotecan (1029) 1029
animals (982) 982
middle aged (946) 946
pharmacology & pharmacy (920) 920
aged (885) 885
adult (816) 816
camptothecin - adverse effects (666) 666
camptothecin - therapeutic use (640) 640
antineoplastic combined chemotherapy protocols - therapeutic use (639) 639
camptothecin - pharmacology (600) 600
cancer (592) 592
antineoplastic agents, phytogenic - pharmacokinetics (575) 575
mice (545) 545
colorectal neoplasms - drug therapy (524) 524
chemotherapy (494) 494
treatment outcome (447) 447
neoplasms - drug therapy (442) 442
antineoplastic agents, phytogenic - administration & dosage (431) 431
camptothecin (419) 419
colorectal cancer (412) 412
cell line, tumor (377) 377
dose-response relationship, drug (365) 365
camptothecin - chemistry (353) 353
antineoplastic combined chemotherapy protocols - adverse effects (345) 345
pharmacokinetics (314) 314
drug administration schedule (307) 307
antineoplastic agents - pharmacokinetics (304) 304
colorectal neoplasms - pathology (302) 302
antineoplastic agents, phytogenic - therapeutic use (300) 300
fluorouracil - administration & dosage (297) 297
medicine & public health (297) 297
care and treatment (286) 286
physical sciences (269) 269
antineoplastic agents - administration & dosage (267) 267
pharmacology/toxicology (266) 266
antineoplastic combined chemotherapy protocols - administration & dosage (265) 265
chemistry (262) 262
antineoplastic agents (255) 255
antineoplastic agents, phytogenic - adverse effects (250) 250
camptothecin - blood (250) 250
research (247) 247
rats (241) 241
antimitotic agents (238) 238
antineoplastic agents - pharmacology (236) 236
antineoplastic agents, phytogenic - pharmacology (233) 233
antineoplastic agents - therapeutic use (225) 225
drug delivery systems (223) 223
area under curve (221) 221
drug therapy (219) 219
infusions, intravenous (218) 218
glucuronosyltransferase - genetics (217) 217
analysis (215) 215
topoisomerase i inhibitors (212) 212
mice, nude (211) 211
tumors (200) 200
camptothecin - metabolism (199) 199
cancer research (199) 199
metastasis (197) 197
sn-38 (195) 195
leucovorin - administration & dosage (192) 192
drugs (189) 189
aged, 80 and over (187) 187
lung neoplasms - drug therapy (183) 183
xenograft model antitumor assays (183) 183
neoplasm metastasis (182) 182
maximum tolerated dose (180) 180
toxicity (180) 180
organoplatinum compounds - administration & dosage (169) 169
diarrhea - chemically induced (166) 166
cpt-11 (164) 164
tissue distribution (162) 162
antineoplastic combined chemotherapy protocols - pharmacokinetics (157) 157
neutropenia - chemically induced (157) 157
antineoplastic agents - adverse effects (155) 155
disease-free survival (151) 151
biochemistry & molecular biology (149) 149
clinical trials (147) 147
chemistry, multidisciplinary (146) 146
genotype (144) 144
adenocarcinoma - drug therapy (142) 142
administration, oral (141) 141
pharmacology (139) 139
antineoplastic agents, phytogenic - chemistry (136) 136
camptothecin - toxicity (136) 136
deoxycytidine - analogs & derivatives (133) 133
mice, inbred balb c (133) 133
colorectal neoplasms - genetics (132) 132
neoplasms - metabolism (130) 130
survival analysis (130) 130
cell survival - drug effects (128) 128
chromatography, high pressure liquid (126) 126
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2817) 2817
Japanese (56) 56
Chinese (22) 22
French (13) 13
German (5) 5
Italian (1) 1
Portuguese (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 06/2009, Volume 27, Issue 16, pp. 2604 - 2614
...) pharmacokinetics and neutropenia in cancer patients. Patients and Methods Pharmacokinetic, genetic, and clinical data were obtained from 85 advanced cancer patients treated... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Multivariate Analysis | Glucuronides - pharmacokinetics | Hepatocyte Nuclear Factor 1-alpha - genetics | Colorectal Neoplasms - genetics | Humans | Middle Aged | Biotransformation - genetics | Male | Organic Anion Transporters - metabolism | Patient Selection | Glucuronosyltransferase - genetics | Antineoplastic Agents, Phytogenic - administration & dosage | Organic Anion Transporters - genetics | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Camptothecin - administration & dosage | Female | Multidrug Resistance-Associated Proteins - genetics | Neutropenia - chemically induced | Neutropenia - genetics | Antineoplastic Agents, Phytogenic - pharmacokinetics | Colorectal Neoplasms - metabolism | Antineoplastic Agents, Phytogenic - adverse effects | Camptothecin - analogs & derivatives | Camptothecin - pharmacokinetics | Camptothecin - adverse effects | Genetic Predisposition to Disease | Drug Administration Schedule | Risk Assessment | Risk Factors | Treatment Outcome | Polymorphism, Genetic | Bilirubin - blood | Phenotype | Glucuronosyltransferase - metabolism | Aged | Solute Carrier Organic Anion Transporter Family Member 1b1 | Multidrug Resistance-Associated Proteins - metabolism | Index Medicus | Original Reports | Gic7 | Faze
Journal Article
Current medicinal chemistry, ISSN 0929-8673, 01/2017, Volume 24, Issue 2, pp. 193 - 214
.... These shortcomings include low targeting specificity, severe side effects (due to high doses) and poor pharmacokinetics... 
Cytotoxicity | Chemotherapy | Metal organic frameworks (MOFs) | Loading | Release | Cancer | Pharmacology & Pharmacy | Biochemistry & Molecular Biology | Life Sciences & Biomedicine | Chemistry, Medicinal | Science & Technology | Humans | Succinates - pharmacokinetics | Antineoplastic Agents - administration & dosage | Busulfan - administration & dosage | Organoplatinum Compounds - pharmacology | Drug Carriers | Nanoparticles | Fluorouracil - administration & dosage | Organoplatinum Compounds - pharmacokinetics | Camptothecin - administration & dosage | Antineoplastic Agents - pharmacokinetics | Doxorubicin - administration & dosage | Camptothecin - pharmacokinetics | Busulfan - pharmacokinetics | Polymers - chemical synthesis | Doxorubicin - pharmacokinetics | Organometallic Compounds - chemical synthesis | Topotecan - pharmacokinetics | Cell Line, Tumor | Topotecan - administration & dosage | Organometallic Compounds - chemistry | Polymers - chemistry | Porosity | Fluorouracil - pharmacokinetics | Succinates - pharmacology | Drug carriers | Drug delivery systems | 5-Fluorouracil | Biodegradability | Metals | Polyelectrolytes | Drug delivery | Doxorubicin | Biomedical materials | Catalysis | Methotrexate | Polymers | Metal ions | Biodegradation | Medical imaging | Pharmacology | Tamoxifen | Cisplatin | Side effects | In vivo methods and tests | Liposomes | Pharmacokinetics | Metal-organic frameworks
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2003, Volume 9, Issue 9, pp. 3246 - 3253
.... Experimental Design: Irinotecan was administered to 65 cancer patients as a 90-min infusion (dose, 200–350 mg/m 2 ), and pharmacokinetic data were obtained during the first cycle... 
P-Glycoprotein/genetics | Multidrug Resistance-Associated Proteins/genetics | Cytochrome P-450 Enzyme System/genetics | Humans | Male | Carboxylesterase/genetics | Glucuronic Acids/chemistry | Middle aged | Neoplasm Proteins/genetics | Adult | Female | Gene Frequency | Genotype | Membrane Transport Proteins/genetics | Polymorphism, Genetic | Homozygote | Phenotype | DNA-Binding Proteins/genetics | Models, Biological | Alleles | Adenosine Triphosphate/genetics | Cell Line, Tumor | Protein Binding | ATP-Binding Cassette Transporters/genetics | Camptothecin/analogs & derivatives/pharmacokinetics/pharmacology | Aged | Research Support, U.S. Gov't, P.H.S | Glucuronosyltransferase/genetics | Cytochrome P-450 CYP3A | Middle Aged | Adenosine Triphosphate - genetics | Glucuronosyltransferase - genetics | ATP-Binding Cassette Transporters - genetics | Membrane Transport Proteins - genetics | Multidrug Resistance-Associated Proteins - genetics | Glucuronates - chemistry | Neoplasm Proteins - genetics | Camptothecin - analogs & derivatives | Camptothecin - pharmacokinetics | ATP Binding Cassette Transporter, Subfamily G, Member 2 | DNA-Binding Proteins - genetics | ATP Binding Cassette Transporter, Subfamily B, Member 1 - genetics | Irinotecan | Carboxylesterase - genetics | Cytochrome P-450 Enzyme System - genetics | X-ray Repair Cross Complementing Protein 1 | Camptothecin - pharmacology | Index Medicus
Journal Article
Journal Article
Journal Article
Investigational new drugs, ISSN 0167-6997, 2/2015, Volume 33, Issue 1, pp. 138 - 147
.... This study aimed to evaluate the maximum tolerated regimen (MTR), safety, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab in adult patients with relapsed or refractory metastatic colorectal cancer (mCRC... 
Irinotecan | Medicine & Public Health | Colorectal cancer | Oncology | Maximum tolerated dose | Dose-limiting toxicities | Pharmacology/Toxicology | Cetuximab | Pazopanib | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Science & Technology | Recurrence | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Male | Protein Kinase Inhibitors - adverse effects | Angiogenesis Inhibitors - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Antibodies, Monoclonal, Humanized - pharmacokinetics | Colorectal Neoplasms - drug therapy | Adult | Camptothecin - administration & dosage | Female | Neutropenia - chemically induced | Angiogenesis Inhibitors - adverse effects | Colorectal Neoplasms - metabolism | Camptothecin - analogs & derivatives | Camptothecin - pharmacokinetics | Protein Kinase Inhibitors - pharmacokinetics | Topoisomerase I Inhibitors - pharmacokinetics | Antibodies, Monoclonal, Humanized - adverse effects | Camptothecin - adverse effects | Pyrimidines - administration & dosage | Topoisomerase I Inhibitors - administration & dosage | Treatment Outcome | Angiogenesis Inhibitors - pharmacokinetics | Sulfonamides - pharmacokinetics | Protein Kinase Inhibitors - administration & dosage | Maximum Tolerated Dose | Topoisomerase I Inhibitors - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Sulfonamides - adverse effects | Aged | Sulfonamides - administration & dosage | Complications and side effects | Dosage and administration | Research | Pharmacokinetics | Drug therapy | Studies | Inhibitor drugs | Response rates | Clinical trials | FDA approval | Kinases | Pharmaceutical sciences | Index Medicus
Journal Article